AL 323
Alternative Names: AL-323Latest Information Update: 28 Apr 2024
At a glance
- Originator Althera Pharmaceuticals
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for clinical-Phase-Unknown development in Cardiovascular-disorders in USA
- 30 Mar 2021 AL 323 is available for licensing as of 30 Mar 2021. https://www.altherapharma.com/copy-of-contact-us
- 26 Mar 2021 Clinical trial in Cardiovascular disorders in USA (unspecified route) before March 2021 (Althera Pharmaceuticals pipeline, March 2021)